MedTrace Logo

A Long Term, Safety Study of Apricitabine in HIV-infected Subjects

NCT00367952 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2011-06-23

No results posted yet for this study

Summary

The study will examine how safe and effective apricitabine is when given long term (as ongoing treatment) to HIV patients who have already completed the AVX-201 trial

Conditions

  • HIV Infection

Interventions

DRUG

apricitabine

800mg apricitabine twice daily orally for 96 weeks

Sponsors & Collaborators

  • Avexa

    lead INDUSTRY

Principal Investigators

  • Susan W Cox, Ph D · Avexa

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00367952 on ClinicalTrials.gov